Last reviewed · How we verify
Methylphenidate Hydrochloride 18 MG
At a glance
| Generic name | Methylphenidate Hydrochloride 18 MG |
|---|---|
| Also known as | Concerta |
| Sponsor | Monash Medical Centre |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Orexin s Role in the Neurobiology of Substance Use Disorder (NA)
- Benefits of ADHD Treatment in Detained People (PHASE3)
- Adjunctive Methylphenidate ER in Patients With Schizophrenia to Improve Functional and Cognitive Outcomes (PHASE2)
- The Effects of Methylphenidate on Symptomatology in Individuals With Borderline Personality Disorder (EARLY_PHASE1)
- Real-World Evidence of Duration of Effect of Adhansia XR (Extended-Release) for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) (PHASE4)
- Efficacy and Safety of Methylphenidate HCl ER Capsules in Children and Adolescents With ADHD (PHASE3)
- Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder (PHASE2)
- FASST - Fetal Alcohol Spectrum Stimulant Trial (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Methylphenidate Hydrochloride 18 MG CI brief — competitive landscape report
- Methylphenidate Hydrochloride 18 MG updates RSS · CI watch RSS
- Monash Medical Centre portfolio CI